Loading...

SCYNEXIS, Inc.

SCYXNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.02
$-0.03(-2.86%)
U.S. Market opens in 8h 28m

SCYNEXIS, Inc. Fundamental Analysis

SCYNEXIS, Inc. (SCYX) shows weak financial fundamentals with a PE ratio of -5.21, profit margin of -41.79%, and ROE of -19.05%. The company generates $0.0B in annual revenue with weak year-over-year growth of -97.33%.

Key Strengths

Cash Position90.13%
PEG Ratio-0.23
Current Ratio7.04

Areas of Concern

ROE-19.05%
Operating Margin-77.93%
We analyze SCYX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -118.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-118.3/100

We analyze SCYX's fundamental strength across five key dimensions:

Efficiency Score

Weak

SCYX struggles to generate sufficient returns from assets.

ROA > 10%
-14.58%

Valuation Score

Excellent

SCYX trades at attractive valuation levels.

PE < 25
-5.21
PEG Ratio < 2
-0.23

Growth Score

Weak

SCYX faces weak or negative growth trends.

Revenue Growth > 5%
-97.33%
EPS Growth > 10%
-1.31%

Financial Health Score

Excellent

SCYX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.04
Current Ratio > 1
7.04

Profitability Score

Weak

SCYX struggles to sustain strong margins.

ROE > 15%
-1904.59%
Net Margin ≥ 15%
-41.79%
Positive Free Cash Flow
No

Key Financial Metrics

Is SCYX Expensive or Cheap?

P/E Ratio

SCYX trades at -5.21 times earnings. This suggests potential undervaluation.

-5.21

PEG Ratio

When adjusting for growth, SCYX's PEG of -0.23 indicates potential undervaluation.

-0.23

Price to Book

The market values SCYNEXIS, Inc. at 0.91 times its book value. This may indicate undervaluation.

0.91

EV/EBITDA

Enterprise value stands at 3.97 times EBITDA. This is generally considered low.

3.97

How Well Does SCYX Make Money?

Net Profit Margin

For every $100 in sales, SCYNEXIS, Inc. keeps $-41.79 as profit after all expenses.

-41.79%

Operating Margin

Core operations generate -77.93 in profit for every $100 in revenue, before interest and taxes.

-77.93%

ROE

Management delivers $-19.05 in profit for every $100 of shareholder equity.

-19.05%

ROA

SCYNEXIS, Inc. generates $-14.58 in profit for every $100 in assets, demonstrating efficient asset deployment.

-14.58%

Following the Money - Real Cash Generation

Operating Cash Flow

SCYNEXIS, Inc. generates limited operating cash flow of $-5.42M, signaling weaker underlying cash strength.

$-5.42M

Free Cash Flow

SCYNEXIS, Inc. generates weak or negative free cash flow of $-5.42M, restricting financial flexibility.

$-5.42M

FCF Per Share

Each share generates $-0.12 in free cash annually.

$-0.12

FCF Yield

SCYX converts -11.54% of its market value into free cash.

-11.54%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.21

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.23

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.91

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.23

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.19

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.30

vs 25 benchmark

How SCYX Stacks Against Its Sector Peers

MetricSCYX ValueSector AveragePerformance
P/E Ratio-5.2128.81 Better (Cheaper)
ROE-19.05%643.00% Weak
Net Margin-41.79%-44312.00% (disorted) Weak
Debt/Equity0.040.36 Strong (Low Leverage)
Current Ratio7.044.50 Strong Liquidity
ROA-14.58%-17799.00% (disorted) Weak

SCYX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SCYNEXIS, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

257.88%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

95.42%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.72%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ